Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Continuous Renal Replacement Therapy Market by Product (Dialysates and Replacement Fluids, Disposables, CRRT Systems), by Modality (Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodiafiltration (CVVHDF), Continuous Venovenous Haemodialysis (CVVHD), Slow Continuous Ultrafiltration (SCUF)), by Age Group (Adults, Pediatrics): Global Opportunity Analysis and Industry Forecast, 2021-2031

A11923

Pages: 323

Charts: 66

Tables: 189

Continuous Renal Replacement Therapy Market Research, 2031

The global Continuous Renal Replacement Therapy Market Size was valued at $1.3 billion in 2021, and is projected to reach $2.6 billion by 2031, growing at a CAGR of 7.7% from 2022 to 2031. Continuous renal replacement therapy (CRRT) is a slow and smooth continuous extracorporeal blood purification process. It is usually implemented over 24 hours to several days with gentle removal of fluid and excess uremic toxins. This technique is usually based on the physiological principles of diffusion, ultrafiltration, convection, and adsorption.

[COVIDIMPACTSTATEMENT]

The key factors which drive Continuous Renal Replacement Therapy Market Growth are rise in the incidence of Acute Kidney Injury (AKI), increase in the incidence of sepsis and a surge in the adoption various key strategies by key players operating in market. In addition, rise in the demand of continuous renal replacement therapy worldwide is the major factor that boosts the growth of the market. For instance, according to the International Society of Nephrology (INR), in 2020 around 13.3 million people were estimated to have suffered from acute kidney injury. Furthermore, the rise in the geriatric population globally and increase in the prevalence of kidney-related diseases further boost the growth of the market. Furthermore, rise in technologically advanced CRRT products for pediatrics drives the growth of the market. For instance, in December, 2020, Medtronic plc. launched the pediatric dialysis emergency machine, named as Carpediem Cardio-Renal. This technology is indicated for use in patients who require hemofiltration or hemodialysis therapy due to acute renal fluid overload or damage. It is designed to give patients who weigh among 2.5 and 10 kilos continuous renal replacement therapy (CRRT).  However, high cost associated with CRRT devices in developing countries are the key factors likely to hamper the growth of the market. For instance, according to NCBI, it was estimated that the cost of continuous renal replacement therapy is around $389-600$ per day. In addition, the lack of awareness of continuous renal replacement therapy in developing countries like Brazil and South Africa due to inadequate funding, poor health care infrastructure, insufficient human resources, and geographic distance is the major factor hampering the growth of the market during the forecast period. In addition rise in government initiatives for regulatory approval will provide lucrative Continuous Renal Replacement Therapy Market Opportunity.

The global Continuous Renal Replacement Therapy Market Size was valued at $1.3 billion in 2021, and is projected to reach $2.6 billion by 2031, growing at a CAGR of 7.7% from 2022 to 2031.The continuous renal replacement therapy market is segmented on the basis of product, modality, age group, and region. Depending on product, the market is classified into dialysates and replacement fluids, disposables, and CRRT systems. Disposables segment is further categorized into hemofilters, bloodline sets and tubes, and other disposables. On the basis of modality, the market is classified into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). According to age group, the market is segmented into pediatric, and adults. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

By Product Segment Review

By product, the dialysates and replacement fluids segment generated the highest revenue in the continuous renal replacement therapy market in 2021 owing to rise in the incidence of acute kidney injury which has increased the demand for CRRT. The Disposables segment is expected to witness considerable market growth during the forecast period, owing to the rise in the prevalence of kidney disorders along with rise in geriatric population.

[PRODUCTGRAPH]

By Modality Segment Review

By modality, the continuous venovenous hemofiltration (CVVH) segment generated highest Continuous Renal Replacement Therapy Market Share in the continuous renal replacement therapy market in 2021, as CVVH can remove large volumes of fluid while avoiding the hypotensive episodes caused by intermittent hemodialysis and its intermittent removal of large volumes of fluid which is creating demand. The Continuous Venovenous Hemodiafiltration (CVVHDF) segment is expected to witness considerable market growth during the forecast period. As CVVHD is an effective treatment in patients suffering from acute renal failure. Continuous veno-venous hemodialysis therapy has many technical advantages and is suitable for the geriatric population across the world are the key factor that drives the growth of the market.

[MODALITYGRAPH]

By Age Group Segment Review

By age group, the adults segment generated the highest Continuous Renal Replacement Therapy Market Share  in 2021, owing to various regulatory approvals for the adult CRRT, and rise in development of novel products for CRRT. Along with this, adoption of various growth strategies by various market players are creating lucrative opportunities in the segment. The Pediatrics segment is expected to witness considerable market growth during the forecast period, owing to the rise in the prevalence of actue kidney disorders among pediatrics across the world.

[AGEGROUPGRAPH]

By Region Segment Review

By region, Asia-Pacific accounted for the largest market share in Continuous Renal Replacement Therapy Industry in 2021 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to increase in number of initiatives along with enhanced investments for the overall R&D of CRRT products. In addition, surge in focus of leading manufacturers on expanding their geographical presence in emerging.  North America is anticipated to witness lucrative growth. Due to high-unmet medical needs pertaining to the target disease segment, such as diabetes, hypertension, and chronic kidney disease, coupled with rising healthcare expenditure in the region are some key factors attributing to market growth.

[REGIONGRAPH]

The major companies profiled in Continuous Renal Replacement Therapy Industry include Anjue Medical Equipment Co. Ltd., Asahi Kasei Corporation, B. Braun Melsungen AG, Chongqing Shanwaishan Science and Technology Co. Ltd., Cytosorbents, Infomed SA, Medica S.p.A, Medical Components Inc., Medites Pharma spol. s.r.o., Medtronic plc., Nikkiso Co. Ltd., Ningbo Tianyi Medical Devices Co. Ltd., Nipro Corporation, SWS Hemodialysis Care Co. Ltd., Toray Industries Inc., Baxter International Inc., and Fresenius Medical Care AG & Co. KGaA

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the continuous renal replacement therapy market analysis from 2021 to 2031 to identify the prevailing continuous renal replacement therapy market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the continuous renal replacement therapy market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global continuous renal replacement therapy market trends, key players, market segments, application areas, and market growth strategies.

 Key Market Segments

  • By Product
    • Dialysates and Replacement Fluids
    • Disposables
      • Type
        • Hemofilters
        • Bloodline Sets & Tubes
        • Other Disposables
    • CRRT Systems
  • By Modality
    • Slow Continuous Ultrafiltration (SCUF)
    • Continuous Venovenous Hemofiltration (CVVH)
    • Continuous Venovenous Hemodiafiltration (CVVHDF)
    • Continuous Venovenous Haemodialysis (CVVHD)
  • By Age Group
    • Adults
    • Pediatrics
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of LAMEA
    • LAMEA
      • Brazil
      • Saudi Arabia
      • South Africa
      • Rest of LAMEA

 
Key Market Players

  • Medica S.p.A
  • Baxter International
  • Medical Components Inc.
  • Chongqing Shanwaishan Science and Technology
  • Cytosorbents
  • Anjue Medical Equipment Co. Ltd
  • Medites Pharma spol. s.r.o
  • B. Braun Melsungen Ag
  • Ningbo Tianyi Medical Devices
  • Medtronic plc
  • Nipro Corporation
  • SWS Hemodialysis Care
  • Asahi Kasei Corporation
  • Toray Industries Inc.
  • Infomed SA
  • Fresenius Medical Care
  • NIKKISO Co. Ltd

  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Dialysates and Replacement Fluids

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Disposables

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

      • 4.3.4 Disposables Continuous Renal Replacement Therapy Market by Type

        • 4.3.4.1 Hemofilters Market size and forecast, by region
        • 4.3.4.2 Bloodline Sets & Tubes Market size and forecast, by region
        • 4.3.4.3 Other Disposables Market size and forecast, by region

    • 4.4 CRRT Systems

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

  • CHAPTER 5: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Continuous Venovenous Hemofiltration (CVVH)

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Continuous Venovenous Hemodiafiltration (CVVHDF)

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

    • 5.4 Continuous Venovenous Haemodialysis (CVVHD)

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market analysis by country

    • 5.5 Slow Continuous Ultrafiltration (SCUF)

      • 5.5.1 Key market trends, growth factors and opportunities

      • 5.5.2 Market size and forecast, by region

      • 5.5.3 Market analysis by country

  • CHAPTER 6: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Adults

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Pediatrics

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

  • CHAPTER 7: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 North America

      • 7.2.1 Key trends and opportunities

      • 7.2.2 North America Market size and forecast, by Product

        • 7.2.2.1 North America Disposables Continuous Renal Replacement Therapy Market by Type

      • 7.2.3 North America Market size and forecast, by Modality

      • 7.2.4 North America Market size and forecast, by Age Group

      • 7.2.5 North America Market size and forecast, by country

        • 7.2.5.1 U.S.
          • 7.2.5.1.1 Market size and forecast, by Product
          • 7.2.5.1.2 Market size and forecast, by Modality
          • 7.2.5.1.3 Market size and forecast, by Age Group
        • 7.2.5.2 Canada
          • 7.2.5.2.1 Market size and forecast, by Product
          • 7.2.5.2.2 Market size and forecast, by Modality
          • 7.2.5.2.3 Market size and forecast, by Age Group
        • 7.2.5.3 Mexico
          • 7.2.5.3.1 Market size and forecast, by Product
          • 7.2.5.3.2 Market size and forecast, by Modality
          • 7.2.5.3.3 Market size and forecast, by Age Group

    • 7.3 Europe

      • 7.3.1 Key trends and opportunities

      • 7.3.2 Europe Market size and forecast, by Product

        • 7.3.2.1 Europe Disposables Continuous Renal Replacement Therapy Market by Type

      • 7.3.3 Europe Market size and forecast, by Modality

      • 7.3.4 Europe Market size and forecast, by Age Group

      • 7.3.5 Europe Market size and forecast, by country

        • 7.3.5.1 Germany
          • 7.3.5.1.1 Market size and forecast, by Product
          • 7.3.5.1.2 Market size and forecast, by Modality
          • 7.3.5.1.3 Market size and forecast, by Age Group
        • 7.3.5.2 France
          • 7.3.5.2.1 Market size and forecast, by Product
          • 7.3.5.2.2 Market size and forecast, by Modality
          • 7.3.5.2.3 Market size and forecast, by Age Group
        • 7.3.5.3 UK
          • 7.3.5.3.1 Market size and forecast, by Product
          • 7.3.5.3.2 Market size and forecast, by Modality
          • 7.3.5.3.3 Market size and forecast, by Age Group
        • 7.3.5.4 Italy
          • 7.3.5.4.1 Market size and forecast, by Product
          • 7.3.5.4.2 Market size and forecast, by Modality
          • 7.3.5.4.3 Market size and forecast, by Age Group
        • 7.3.5.5 Spain
          • 7.3.5.5.1 Market size and forecast, by Product
          • 7.3.5.5.2 Market size and forecast, by Modality
          • 7.3.5.5.3 Market size and forecast, by Age Group
        • 7.3.5.6 Rest of Europe
          • 7.3.5.6.1 Market size and forecast, by Product
          • 7.3.5.6.2 Market size and forecast, by Modality
          • 7.3.5.6.3 Market size and forecast, by Age Group

    • 7.4 Asia-Pacific

      • 7.4.1 Key trends and opportunities

      • 7.4.2 Asia-Pacific Market size and forecast, by Product

        • 7.4.2.1 Asia-Pacific Disposables Continuous Renal Replacement Therapy Market by Type

      • 7.4.3 Asia-Pacific Market size and forecast, by Modality

      • 7.4.4 Asia-Pacific Market size and forecast, by Age Group

      • 7.4.5 Asia-Pacific Market size and forecast, by country

        • 7.4.5.1 China
          • 7.4.5.1.1 Market size and forecast, by Product
          • 7.4.5.1.2 Market size and forecast, by Modality
          • 7.4.5.1.3 Market size and forecast, by Age Group
        • 7.4.5.2 Japan
          • 7.4.5.2.1 Market size and forecast, by Product
          • 7.4.5.2.2 Market size and forecast, by Modality
          • 7.4.5.2.3 Market size and forecast, by Age Group
        • 7.4.5.3 India
          • 7.4.5.3.1 Market size and forecast, by Product
          • 7.4.5.3.2 Market size and forecast, by Modality
          • 7.4.5.3.3 Market size and forecast, by Age Group
        • 7.4.5.4 Australia
          • 7.4.5.4.1 Market size and forecast, by Product
          • 7.4.5.4.2 Market size and forecast, by Modality
          • 7.4.5.4.3 Market size and forecast, by Age Group
        • 7.4.5.5 South Korea
          • 7.4.5.5.1 Market size and forecast, by Product
          • 7.4.5.5.2 Market size and forecast, by Modality
          • 7.4.5.5.3 Market size and forecast, by Age Group
        • 7.4.5.6 Rest of LAMEA
          • 7.4.5.6.1 Market size and forecast, by Product
          • 7.4.5.6.2 Market size and forecast, by Modality
          • 7.4.5.6.3 Market size and forecast, by Age Group

    • 7.5 LAMEA

      • 7.5.1 Key trends and opportunities

      • 7.5.2 LAMEA Market size and forecast, by Product

        • 7.5.2.1 LAMEA Disposables Continuous Renal Replacement Therapy Market by Type

      • 7.5.3 LAMEA Market size and forecast, by Modality

      • 7.5.4 LAMEA Market size and forecast, by Age Group

      • 7.5.5 LAMEA Market size and forecast, by country

        • 7.5.5.1 Brazil
          • 7.5.5.1.1 Market size and forecast, by Product
          • 7.5.5.1.2 Market size and forecast, by Modality
          • 7.5.5.1.3 Market size and forecast, by Age Group
        • 7.5.5.2 Saudi Arabia
          • 7.5.5.2.1 Market size and forecast, by Product
          • 7.5.5.2.2 Market size and forecast, by Modality
          • 7.5.5.2.3 Market size and forecast, by Age Group
        • 7.5.5.3 South Africa
          • 7.5.5.3.1 Market size and forecast, by Product
          • 7.5.5.3.2 Market size and forecast, by Modality
          • 7.5.5.3.3 Market size and forecast, by Age Group
        • 7.5.5.4 Rest of LAMEA
          • 7.5.5.4.1 Market size and forecast, by Product
          • 7.5.5.4.2 Market size and forecast, by Modality
          • 7.5.5.4.3 Market size and forecast, by Age Group

  • CHAPTER 8: COMPANY LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Key developments

  • CHAPTER 9: COMPANY PROFILES

    • 9.1 Fresenius Medical Care

      • 9.1.1 Company overview

      • 9.1.2 Company snapshot

      • 9.1.3 Operating business segments

      • 9.1.4 Product portfolio

      • 9.1.5 Business performance

      • 9.1.6 Key strategic moves and developments

    • 9.2 Baxter International

      • 9.2.1 Company overview

      • 9.2.2 Company snapshot

      • 9.2.3 Operating business segments

      • 9.2.4 Product portfolio

      • 9.2.5 Business performance

      • 9.2.6 Key strategic moves and developments

    • 9.3 Toray Industries Inc.

      • 9.3.1 Company overview

      • 9.3.2 Company snapshot

      • 9.3.3 Operating business segments

      • 9.3.4 Product portfolio

      • 9.3.5 Business performance

      • 9.3.6 Key strategic moves and developments

    • 9.4 SWS Hemodialysis Care

      • 9.4.1 Company overview

      • 9.4.2 Company snapshot

      • 9.4.3 Operating business segments

      • 9.4.4 Product portfolio

      • 9.4.5 Business performance

      • 9.4.6 Key strategic moves and developments

    • 9.5 Nipro Corporation

      • 9.5.1 Company overview

      • 9.5.2 Company snapshot

      • 9.5.3 Operating business segments

      • 9.5.4 Product portfolio

      • 9.5.5 Business performance

      • 9.5.6 Key strategic moves and developments

    • 9.6 Ningbo Tianyi Medical Devices

      • 9.6.1 Company overview

      • 9.6.2 Company snapshot

      • 9.6.3 Operating business segments

      • 9.6.4 Product portfolio

      • 9.6.5 Business performance

      • 9.6.6 Key strategic moves and developments

    • 9.7 NIKKISO Co. Ltd

      • 9.7.1 Company overview

      • 9.7.2 Company snapshot

      • 9.7.3 Operating business segments

      • 9.7.4 Product portfolio

      • 9.7.5 Business performance

      • 9.7.6 Key strategic moves and developments

    • 9.8 Medtronic plc

      • 9.8.1 Company overview

      • 9.8.2 Company snapshot

      • 9.8.3 Operating business segments

      • 9.8.4 Product portfolio

      • 9.8.5 Business performance

      • 9.8.6 Key strategic moves and developments

    • 9.9 Medites Pharma spol. s.r.o

      • 9.9.1 Company overview

      • 9.9.2 Company snapshot

      • 9.9.3 Operating business segments

      • 9.9.4 Product portfolio

      • 9.9.5 Business performance

      • 9.9.6 Key strategic moves and developments

    • 9.10 Medical Components Inc.

      • 9.10.1 Company overview

      • 9.10.2 Company snapshot

      • 9.10.3 Operating business segments

      • 9.10.4 Product portfolio

      • 9.10.5 Business performance

      • 9.10.6 Key strategic moves and developments

    • 9.11 Medica S.p.A

      • 9.11.1 Company overview

      • 9.11.2 Company snapshot

      • 9.11.3 Operating business segments

      • 9.11.4 Product portfolio

      • 9.11.5 Business performance

      • 9.11.6 Key strategic moves and developments

    • 9.12 Infomed SA

      • 9.12.1 Company overview

      • 9.12.2 Company snapshot

      • 9.12.3 Operating business segments

      • 9.12.4 Product portfolio

      • 9.12.5 Business performance

      • 9.12.6 Key strategic moves and developments

    • 9.13 Cytosorbents

      • 9.13.1 Company overview

      • 9.13.2 Company snapshot

      • 9.13.3 Operating business segments

      • 9.13.4 Product portfolio

      • 9.13.5 Business performance

      • 9.13.6 Key strategic moves and developments

    • 9.14 Chongqing Shanwaishan Science and Technology

      • 9.14.1 Company overview

      • 9.14.2 Company snapshot

      • 9.14.3 Operating business segments

      • 9.14.4 Product portfolio

      • 9.14.5 Business performance

      • 9.14.6 Key strategic moves and developments

    • 9.15 B. Braun Melsungen Ag

      • 9.15.1 Company overview

      • 9.15.2 Company snapshot

      • 9.15.3 Operating business segments

      • 9.15.4 Product portfolio

      • 9.15.5 Business performance

      • 9.15.6 Key strategic moves and developments

    • 9.16 Asahi Kasei Corporation

      • 9.16.1 Company overview

      • 9.16.2 Company snapshot

      • 9.16.3 Operating business segments

      • 9.16.4 Product portfolio

      • 9.16.5 Business performance

      • 9.16.6 Key strategic moves and developments

    • 9.17 Anjue Medical Equipment Co. Ltd

      • 9.17.1 Company overview

      • 9.17.2 Company snapshot

      • 9.17.3 Operating business segments

      • 9.17.4 Product portfolio

      • 9.17.5 Business performance

      • 9.17.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 2. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR DIALYSATES AND REPLACEMENT FLUIDS, BY REGION, 2021-2031 ($MILLION)
    TABLE 3. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR DIALYSATES AND REPLACEMENT FLUIDS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 4. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR DISPOSABLES, BY REGION, 2021-2031 ($MILLION)
    TABLE 5. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR DISPOSABLES, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 6. GLOBAL DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 7. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, FOR HEMOFILTERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 8. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, FOR BLOODLINE SETS & TUBES, BY REGION, 2021-2031 ($MILLION)
    TABLE 9. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, FOR OTHER DISPOSABLES, BY REGION, 2021-2031 ($MILLION)
    TABLE 10. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR CRRT SYSTEMS, BY REGION, 2021-2031 ($MILLION)
    TABLE 11. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CRRT SYSTEMS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 12. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 13. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH), BY REGION, 2021-2031 ($MILLION)
    TABLE 14. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH), BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 15. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF), BY REGION, 2021-2031 ($MILLION)
    TABLE 16. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF), BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 17. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR CONTINUOUS VENOVENOUS HAEMODIALYSIS (CVVHD), BY REGION, 2021-2031 ($MILLION)
    TABLE 18. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR CONTINUOUS VENOVENOUS HAEMODIALYSIS (CVVHD), BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 19. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR SLOW CONTINUOUS ULTRAFILTRATION (SCUF), BY REGION, 2021-2031 ($MILLION)
    TABLE 20. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR SLOW CONTINUOUS ULTRAFILTRATION (SCUF), BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 21. GLOBAL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 22. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR ADULTS, BY REGION, 2021-2031 ($MILLION)
    TABLE 23. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR ADULTS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 24. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SIZE, FOR PEDIATRICS, BY REGION, 2021-2031 ($MILLION)
    TABLE 25. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET FOR PEDIATRICS, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 26. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 27. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 28. NORTH AMERICA DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 29. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 30. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 31. NORTH AMERICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 32. U.S. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 33. U.S. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 34. U.S. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 35. CANADA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 36. CANADA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 37. CANADA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 38. MEXICO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 39. MEXICO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 40. MEXICO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 41. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 42. EUROPE DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 43. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 44. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 45. EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 46. GERMANY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 47. GERMANY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 48. GERMANY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 49. FRANCE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 50. FRANCE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 51. FRANCE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 52. UK CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 53. UK CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 54. UK CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 55. ITALY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 56. ITALY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 57. ITALY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 58. SPAIN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 59. SPAIN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 60. SPAIN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 61. REST OF EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 62. REST OF EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 63. REST OF EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 64. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 65. ASIA-PACIFIC DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 66. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 67. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 68. ASIA-PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 69. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 70. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 71. CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 72. JAPAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 73. JAPAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 74. JAPAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 75. INDIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 76. INDIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 77. INDIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 78. AUSTRALIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 79. AUSTRALIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 80. AUSTRALIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 81. SOUTH KOREA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 82. SOUTH KOREA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 83. SOUTH KOREA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 84. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 85. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 86. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 87. LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 88. LAMEA DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 89. LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 90. LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 91. LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 92. BRAZIL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 93. BRAZIL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 94. BRAZIL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 95. SAUDI ARABIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 96. SAUDI ARABIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 97. SAUDI ARABIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 98. SOUTH AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 99. SOUTH AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 100. SOUTH AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 101. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021-2031 ($MILLION)
    TABLE 102. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY, 2021-2031 ($MILLION)
    TABLE 103. REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
    TABLE 104.FRESENIUS MEDICAL CARE: COMPANY SNAPSHOT
    TABLE 105.FRESENIUS MEDICAL CARE: OPERATING SEGMENTS
    TABLE 106.FRESENIUS MEDICAL CARE: PRODUCT PORTFOLIO
    TABLE 107.FRESENIUS MEDICAL CARE: NET SALES,
    TABLE 108.FRESENIUS MEDICAL CARE: KEY STRATERGIES
    TABLE 109.BAXTER INTERNATIONAL: COMPANY SNAPSHOT
    TABLE 110.BAXTER INTERNATIONAL: OPERATING SEGMENTS
    TABLE 111.BAXTER INTERNATIONAL: PRODUCT PORTFOLIO
    TABLE 112.BAXTER INTERNATIONAL: NET SALES,
    TABLE 113.BAXTER INTERNATIONAL: KEY STRATERGIES
    TABLE 114.TORAY INDUSTRIES INC.: COMPANY SNAPSHOT
    TABLE 115.TORAY INDUSTRIES INC.: OPERATING SEGMENTS
    TABLE 116.TORAY INDUSTRIES INC.: PRODUCT PORTFOLIO
    TABLE 117.TORAY INDUSTRIES INC.: NET SALES,
    TABLE 118.TORAY INDUSTRIES INC.: KEY STRATERGIES
    TABLE 119.SWS HEMODIALYSIS CARE: COMPANY SNAPSHOT
    TABLE 120.SWS HEMODIALYSIS CARE: OPERATING SEGMENTS
    TABLE 121.SWS HEMODIALYSIS CARE: PRODUCT PORTFOLIO
    TABLE 122.SWS HEMODIALYSIS CARE: NET SALES,
    TABLE 123.SWS HEMODIALYSIS CARE: KEY STRATERGIES
    TABLE 124.NIPRO CORPORATION: COMPANY SNAPSHOT
    TABLE 125.NIPRO CORPORATION: OPERATING SEGMENTS
    TABLE 126.NIPRO CORPORATION: PRODUCT PORTFOLIO
    TABLE 127.NIPRO CORPORATION: NET SALES,
    TABLE 128.NIPRO CORPORATION: KEY STRATERGIES
    TABLE 129.NINGBO TIANYI MEDICAL DEVICES: COMPANY SNAPSHOT
    TABLE 130.NINGBO TIANYI MEDICAL DEVICES: OPERATING SEGMENTS
    TABLE 131.NINGBO TIANYI MEDICAL DEVICES: PRODUCT PORTFOLIO
    TABLE 132.NINGBO TIANYI MEDICAL DEVICES: NET SALES,
    TABLE 133.NINGBO TIANYI MEDICAL DEVICES: KEY STRATERGIES
    TABLE 134.NIKKISO CO. LTD: COMPANY SNAPSHOT
    TABLE 135.NIKKISO CO. LTD: OPERATING SEGMENTS
    TABLE 136.NIKKISO CO. LTD: PRODUCT PORTFOLIO
    TABLE 137.NIKKISO CO. LTD: NET SALES,
    TABLE 138.NIKKISO CO. LTD: KEY STRATERGIES
    TABLE 139.MEDTRONIC PLC: COMPANY SNAPSHOT
    TABLE 140.MEDTRONIC PLC: OPERATING SEGMENTS
    TABLE 141.MEDTRONIC PLC: PRODUCT PORTFOLIO
    TABLE 142.MEDTRONIC PLC: NET SALES,
    TABLE 143.MEDTRONIC PLC: KEY STRATERGIES
    TABLE 144.MEDITES PHARMA SPOL. S.R.O: COMPANY SNAPSHOT
    TABLE 145.MEDITES PHARMA SPOL. S.R.O: OPERATING SEGMENTS
    TABLE 146.MEDITES PHARMA SPOL. S.R.O: PRODUCT PORTFOLIO
    TABLE 147.MEDITES PHARMA SPOL. S.R.O: NET SALES,
    TABLE 148.MEDITES PHARMA SPOL. S.R.O: KEY STRATERGIES
    TABLE 149.MEDICAL COMPONENTS INC.: COMPANY SNAPSHOT
    TABLE 150.MEDICAL COMPONENTS INC.: OPERATING SEGMENTS
    TABLE 151.MEDICAL COMPONENTS INC.: PRODUCT PORTFOLIO
    TABLE 152.MEDICAL COMPONENTS INC.: NET SALES,
    TABLE 153.MEDICAL COMPONENTS INC.: KEY STRATERGIES
    TABLE 154.MEDICA S.P.A: COMPANY SNAPSHOT
    TABLE 155.MEDICA S.P.A: OPERATING SEGMENTS
    TABLE 156.MEDICA S.P.A: PRODUCT PORTFOLIO
    TABLE 157.MEDICA S.P.A: NET SALES,
    TABLE 158.MEDICA S.P.A: KEY STRATERGIES
    TABLE 159.INFOMED SA: COMPANY SNAPSHOT
    TABLE 160.INFOMED SA: OPERATING SEGMENTS
    TABLE 161.INFOMED SA: PRODUCT PORTFOLIO
    TABLE 162.INFOMED SA: NET SALES,
    TABLE 163.INFOMED SA: KEY STRATERGIES
    TABLE 164.CYTOSORBENTS: COMPANY SNAPSHOT
    TABLE 165.CYTOSORBENTS: OPERATING SEGMENTS
    TABLE 166.CYTOSORBENTS: PRODUCT PORTFOLIO
    TABLE 167.CYTOSORBENTS: NET SALES,
    TABLE 168.CYTOSORBENTS: KEY STRATERGIES
    TABLE 169.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: COMPANY SNAPSHOT
    TABLE 170.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: OPERATING SEGMENTS
    TABLE 171.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: PRODUCT PORTFOLIO
    TABLE 172.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: NET SALES,
    TABLE 173.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY: KEY STRATERGIES
    TABLE 174.B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
    TABLE 175.B. BRAUN MELSUNGEN AG: OPERATING SEGMENTS
    TABLE 176.B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
    TABLE 177.B. BRAUN MELSUNGEN AG: NET SALES,
    TABLE 178.B. BRAUN MELSUNGEN AG: KEY STRATERGIES
    TABLE 179.ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
    TABLE 180.ASAHI KASEI CORPORATION: OPERATING SEGMENTS
    TABLE 181.ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
    TABLE 182.ASAHI KASEI CORPORATION: NET SALES,
    TABLE 183.ASAHI KASEI CORPORATION: KEY STRATERGIES
    TABLE 184.ANJUE MEDICAL EQUIPMENT CO. LTD: COMPANY SNAPSHOT
    TABLE 185.ANJUE MEDICAL EQUIPMENT CO. LTD: OPERATING SEGMENTS
    TABLE 186.ANJUE MEDICAL EQUIPMENT CO. LTD: PRODUCT PORTFOLIO
    TABLE 187.ANJUE MEDICAL EQUIPMENT CO. LTD: NET SALES,
    TABLE 188.ANJUE MEDICAL EQUIPMENT CO. LTD: KEY STRATERGIES

  • LIST OF FIGURES

  • FIGURE 1.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET SEGMENTATION
    FIGURE 2.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031
    FIGURE 3.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,BY PRODUCT,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DIALYSATES AND REPLACEMENT FLUIDS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF DISPOSABLES CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CRRT SYSTEMS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 16.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,BY MODALITY,2021(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH) CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF) CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CONTINUOUS VENOVENOUS HAEMODIALYSIS (CVVHD) CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SLOW CONTINUOUS ULTRAFILTRATION (SCUF) CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 21.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,BY AGE GROUP,2021(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ADULTS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF PEDIATRICS CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031(%)
    FIGURE 24.CONTINUOUS RENAL REPLACEMENT THERAPY MARKET BY REGION,2021
    FIGURE 25.U.S. CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 26.CANADA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 27.MEXICO CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 28.GERMANY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 29.FRANCE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 30.UK CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 31.ITALY CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 32.SPAIN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 33.REST OF EUROPE CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 34.CHINA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 35.JAPAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 36.INDIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 37.AUSTRALIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 38.SOUTH KOREA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 39.REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 40.BRAZIL CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 41.SAUDI ARABIA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 42.SOUTH AFRICA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 43.REST OF LAMEA CONTINUOUS RENAL REPLACEMENT THERAPY MARKET,2021-2031($MILLION)
    FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 48.COMPETITIVE DASHBOARD
    FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 50.FRESENIUS MEDICAL CARE.: NET SALES ,($MILLION)
    FIGURE 51.BAXTER INTERNATIONAL.: NET SALES ,($MILLION)
    FIGURE 52.TORAY INDUSTRIES INC..: NET SALES ,($MILLION)
    FIGURE 53.SWS HEMODIALYSIS CARE.: NET SALES ,($MILLION)
    FIGURE 54.NIPRO CORPORATION.: NET SALES ,($MILLION)
    FIGURE 55.NINGBO TIANYI MEDICAL DEVICES.: NET SALES ,($MILLION)
    FIGURE 56.NIKKISO CO. LTD.: NET SALES ,($MILLION)
    FIGURE 57.MEDTRONIC PLC.: NET SALES ,($MILLION)
    FIGURE 58.MEDITES PHARMA SPOL. S.R.O.: NET SALES ,($MILLION)
    FIGURE 59.MEDICAL COMPONENTS INC..: NET SALES ,($MILLION)
    FIGURE 60.MEDICA S.P.A.: NET SALES ,($MILLION)
    FIGURE 61.INFOMED SA.: NET SALES ,($MILLION)
    FIGURE 62.CYTOSORBENTS.: NET SALES ,($MILLION)
    FIGURE 63.CHONGQING SHANWAISHAN SCIENCE AND TECHNOLOGY.: NET SALES ,($MILLION)
    FIGURE 64.B. BRAUN MELSUNGEN AG.: NET SALES ,($MILLION)
    FIGURE 65.ASAHI KASEI CORPORATION.: NET SALES ,($MILLION)
    FIGURE 66.ANJUE MEDICAL EQUIPMENT CO. LTD.: NET SALES ,($MILLION)

Purchase Full Report of
Continuous Renal Replacement Therapy Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved